A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of concomitant ramucirumab on the
pharmacokinetics of docetaxel in participants with advanced malignant solid tumors.
Participants who do not complete both Cycle 1, Day 1, and Cycle 2, Day 1 according to
schedule will be replaced for the purpose of analysis; these participants may continue to
receive study therapy. No dose reductions, delayed or missed doses are allowed during Cycles
1 and 2.